EUCTR2008-006215-20-DK进行中（未招募）1 期
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trialof MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient is between 21 and 70 years of age.
- •2. Patient has type 2 diabetes mellitus and meets one of the following criteria:
- •On a stable dose of Lantus insulin monotherapy >=15 units/day for at least 6 weeks and has a Visit 1/Screening Visit A1C of =7.5% and ?11.0%
- •On any injectable insulin (other than Lantus) at a stable dose of >=15 units/day, either alone or in combination with an oral monotherapy agent for at least 6 weeks and has a Visit 1/Screening A1C of =7.0% and ?10.5%
- •On any injectable insulin at a stable dose of >=15 units/day, in combination with two oral agents for at least 6 weeks and has a Visit 1/Screening A1C of =6.5% and <=10.0%
- •3. Patient is a male or a female who is highly unlikely to conceive (i.e., patient is a male, patient is not of reproductive potential, patient is of reproductive potential and agrees to remain abstinent or use 2 acceptable methods of birth control).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis.
- •2. Patient has received more than 1 week of dosing of TZD therapy within the past 8 weeks.
- •3. Patient has a history of severe hypoglycemia defined as 2 or more episodes during his/her lifetime or one episode within the past year that resulted in hypoglycemic seizures and/or cerebral impairment (e.g. coma, severe confusion, etc.) or patient has had hypoglycemia unawareness (i.e.,fingerstick glucose <50 mg/dL [2.8 mmol/L] without symptoms) within the past 3 months.
- •4. Patient has a contraindication to Lantus insulin.
- •5. Patient meets one of the following medication exclusions:
- •Taking weight loss medication (e.g. orlistat, sibutramine, rimonabant, etc) within 8 weeks of Visit 1/Screening Visit.
- •Currently taking or likely to require treatment with > 14 consecutive days or repeated courses of pharmacological doses of systemic (oral, injectable/parenteral) or ocular corticosteroids during the study. (NOTE: oral corticosteroids used for physiologic replacement therapy (e.g. in patients with adrenal insufficiency) and inhaled, nasal, and topical (i.e. dermatological) corticosteroids are allowed).
- •Currently on or likely to require treatment with warfarin or warfarin-like anticoagulants, digoxin, or any other medication with a narrow therapeutic index.
- •Under treatment with anti-thyroid medication or radioactive iodine for hyperthyroidism.
- •Currently treated or likely to require treatment with the following glaucoma medications: ecothiophate, pilocarpine, or carbachol
- •6. Patient meets one of the following medical exclusions:
- •New or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months
- •Any of the following in the past 6 months: acute coronary syndrome, cerebral vascular accident, or TIA
- •NYHA Class II-IV cardiac status or severe peripheral vascular disease
- •Chronic myopathy or a progressive neurological or neuromuscular disorder
- •Active nephropathy
- •Active liver disease (other than non-alcoholic hepatic steatosis), active viral hepatitis, cirrhosis, or symptomatic gallbladder disease
- •HIV positive
- •Clinically significant hematological disorder
- •History of malignancy < 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer (NOTE: Melanoma, leukemia, myeloproliferative disorders and renal cell carcinoma of any duration are excluded)
- •Ocular herpes, uveitis, or iritis within 3 months prior to screening or has a history of recurrent episodes of any of these three conditions.
- •Poorly controlled hypertension
- •Any other condition which, in the opinion of the investigator, might pose a risk to the patient or make participation not in the patient's best interest, that might confound the results of the study, or interfere with the patient's participation for the full duration of the study
- •7. Patient has undergone surgery within 30 days prior to Visit 1/Screening Visit or has planned major surgery.
- •8. Patient has had coronary artery intervention (e.g. coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the past 6 months
- •9. Patient has had, or is anticipated to have intraocular surgery within 6 months prior to Visit 1 or during the study or has had laser eye surgery within 3 months prior to screening (LASIK is permitted).
- •10. Patient has any existing condition which will prec
研究者
相似试验
已完成
不适用
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insuli-E14 Unspecified diabetes mellitusUnspecified diabetes mellitusE14PER-174-08MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on InsuliType 2 diabetes mellitusMedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitusEUCTR2008-006215-20-FRaboratoires MSD-Chibret87
进行中（未招募）
不适用
A study is to find out whether a new oral drug, laquinimod, given inaddition to the standard/routine treatment is safe and may improvelupus nephritis disease response to treatment.Active Lupus NephritisMedDRA version: 13.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-018329-20-GBTeva Pharmaceutical Industries Ltd.45
进行中（未招募）
不适用
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn?s Disease - NDMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10013099Term: Disease CrohnsCrohn DiseaseEUCTR2008-004276-49-ITTeva Pharmaceutical Industries Ltd.200
进行中（未招募）
1 期
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn’s DiseaseEUCTR2008-004276-49-FRTeva Pharmaceutical Industries Ltd.199